Sravnenie terapii paklitakselom i bevatsizumabom i monoterapii paklitakselom u patsientok s metastaticheskim rakom molochnoy zhelezy

  • Autores: Miller K.1,2,3,4,5,6,7,8,9, Wang M.1,2,3,4,5,6,7,8,9, Gralow J.1,2,3,4,5,6,7,8,9, Dickler M.1,2,3,4,5,6,7,8,9, Cobleigh M.1,2,3,4,5,6,7,8,9, Perez E.A1,2,3,4,5,6,7,8,9, Shenkier T.1,2,3,4,5,6,7,8,9, Davidson N.E1,2,3,4,5,6,7,8,9
  • Afiliações:
    1. Indiana University Cancer Center
    2. Dana-Farber Cancer Institute
    3. Puget Sound Oncology Consortium
    4. Memorial Sloan-Kettering Cancer Center
    5. Rush-Presbyterian-St. Luke's Medical Center
    6. Mayo Clinic
    7. British Columbia Cancer Agency-Vancouver Cancer Center
    8. Evanston Northwestern Healthcare and Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    9. Johns Hopkins Kimmel Comprehensive Cancer Center
  • Edição: Nº 2S (2008)
  • Páginas: 60-68
  • Seção: Articles
  • URL: https://journals.eco-vector.com/2073-4034/article/view/275777
  • ID: 275777

Citar

Texto integral

Resumo

В открытом рандомизированном исследовании III фазы сравнивались эффективность и безопасность терапии паклитакселом с аналогичными показателями при применении паклитаксела и бевацизумаба (Авастина) - моноклонального антитела к фактору роста эндотелия сосудов, в качестве 1-й линии терапии метастатического рака молочной железы (РМЖ). После рандомизации пациенткам назначался паклитаксел в дозе 90 мг/м 2 в 1-й, 8-й и 15-й дни каждые 4 недели либо в виде монотерапии, либо в сочетании с бевацизумабом в дозе 10 мг/кг в 1-й и 15-й дни. Главным критерием эффективности терапии была выживаемость без прогрессирования заболевания, общая выживаемость была дополнительным критерием эффективности. С декабря 2001 по май 2004 г. в исследование были включены в общей сложности 722 пациентки. Бевацизумаб в сочетании с паклитакселом значительно увеличивал выживаемость без прогрессирования заболевания по сравнению с паклитакселом в монотерапии (медиана -11,8 и 5,9 месяца соответственно; относительный риск (ОР) прогрессирования - 0,6; р < 0,001) и повышал частоту объективного ответа (36,9 и 21,2 % соответственно; р<0,001). Тем не менее уровень общей выживаемости был практически одинаковым в обеих группах (медиана - 26,7 и 25,2 месяца соответственно; ОР - 0,88; р = 0,16). У пациенток, получавших паклитаксел в сочетании с бевацизумабом, чаще отмечались: артериальная гипертензия III или IV степени (14,8 по сравнению с 0,0 %, р < 0,001), протеинурия (3,6 по сравнению с 0,0 %, р < 0,001), головная боль (2,2 по сравнению с 0,0 %, р = 0,008) и цереброваскулярная ишемия (1,9 по сравнению с 0,0 %, р = 0,02). У пациенток, получавших паклитаксел и бевацизумаб, чаще встречались инфекции (9,3 по сравнению с 2,9 %, р < 0,001), хотя фебрильная нейтропения отмечалась редко (менее 1 % общего числа). Результаты исследования показали, что применение паклитаксела и бевацизумаба в 1-й линии терапии метастатического РМЖ позволяет увеличить выживаемость без прогрессирования заболевания по сравнению с монотерапией паклитакселом. (Идентификационный номер исследования на ClinicalTrials.gov: NCT00028990.)

Texto integral

Acesso é fechado

Sobre autores

K. Miller

Indiana University Cancer Center; Dana-Farber Cancer Institute; Puget Sound Oncology Consortium; Memorial Sloan-Kettering Cancer Center; Rush-Presbyterian-St. Luke's Medical Center; Mayo Clinic; British Columbia Cancer Agency-Vancouver Cancer Center; Evanston Northwestern Healthcare and Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Johns Hopkins Kimmel Comprehensive Cancer Center

M. Wang

Indiana University Cancer Center; Dana-Farber Cancer Institute; Puget Sound Oncology Consortium; Memorial Sloan-Kettering Cancer Center; Rush-Presbyterian-St. Luke's Medical Center; Mayo Clinic; British Columbia Cancer Agency-Vancouver Cancer Center; Evanston Northwestern Healthcare and Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Johns Hopkins Kimmel Comprehensive Cancer Center

J. Gralow

Indiana University Cancer Center; Dana-Farber Cancer Institute; Puget Sound Oncology Consortium; Memorial Sloan-Kettering Cancer Center; Rush-Presbyterian-St. Luke's Medical Center; Mayo Clinic; British Columbia Cancer Agency-Vancouver Cancer Center; Evanston Northwestern Healthcare and Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Johns Hopkins Kimmel Comprehensive Cancer Center

M. Dickler

Indiana University Cancer Center; Dana-Farber Cancer Institute; Puget Sound Oncology Consortium; Memorial Sloan-Kettering Cancer Center; Rush-Presbyterian-St. Luke's Medical Center; Mayo Clinic; British Columbia Cancer Agency-Vancouver Cancer Center; Evanston Northwestern Healthcare and Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Johns Hopkins Kimmel Comprehensive Cancer Center

M. Cobleigh

Indiana University Cancer Center; Dana-Farber Cancer Institute; Puget Sound Oncology Consortium; Memorial Sloan-Kettering Cancer Center; Rush-Presbyterian-St. Luke's Medical Center; Mayo Clinic; British Columbia Cancer Agency-Vancouver Cancer Center; Evanston Northwestern Healthcare and Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Johns Hopkins Kimmel Comprehensive Cancer Center

E. Perez

Indiana University Cancer Center; Dana-Farber Cancer Institute; Puget Sound Oncology Consortium; Memorial Sloan-Kettering Cancer Center; Rush-Presbyterian-St. Luke's Medical Center; Mayo Clinic; British Columbia Cancer Agency-Vancouver Cancer Center; Evanston Northwestern Healthcare and Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Johns Hopkins Kimmel Comprehensive Cancer Center

T. Shenkier

Indiana University Cancer Center; Dana-Farber Cancer Institute; Puget Sound Oncology Consortium; Memorial Sloan-Kettering Cancer Center; Rush-Presbyterian-St. Luke's Medical Center; Mayo Clinic; British Columbia Cancer Agency-Vancouver Cancer Center; Evanston Northwestern Healthcare and Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Johns Hopkins Kimmel Comprehensive Cancer Center

N. Davidson

Indiana University Cancer Center; Dana-Farber Cancer Institute; Puget Sound Oncology Consortium; Memorial Sloan-Kettering Cancer Center; Rush-Presbyterian-St. Luke's Medical Center; Mayo Clinic; British Columbia Cancer Agency-Vancouver Cancer Center; Evanston Northwestern Healthcare and Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Johns Hopkins Kimmel Comprehensive Cancer Center

Bibliografia

  1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
  2. Gasparini G. Angiogenesis in breast cancer: role in biology, tumor progression, and prognosis. In: Bowcock A, ed. Breast cancer: molecular genetics, pathogenesis, and therapeutics. Totowa, NJ: Humana Press 1999:347-71.
  3. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-69.
  4. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol Rev 1997;18:4-25.
  5. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20: 4368-80.
  6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9: 669-76.
  7. Cobleigh M, Miller K, Langmuir V, et al. Phase II dose escalation trial of Avastin (bevacizumab) in women with previously treated metastatic breast cancer. Breast Cancer Res Treat 2001;69:301.
  8. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-99.
  9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
  10. O'Brien PC, Fleming T. A multiple testing procedure for clinical trials. Biometrics 1979;35: 54956.
  11. Jennison C, Turnbull B. Interim analyses: the repeated confidence interval approach. J R Stat Soc B 1989;51:305-61.
  12. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
  13. Fitzmaurice GM, Laird NM, Shneyer L. An alternative parameterization of the general linear mixture model for longitudinal data with non-ignorable drop-outs. Stat Med 2001;20:1009-21.
  14. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997;15:974-86.
  15. Wagner L, Wang M, Miller K, et al. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. Breast Cancer Res Treat 2006;100(Suppl. 1):S239.
  16. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
  17. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. Erratum N Engl J Med 2007;356:318.
  18. Skillings JR, Johnson D, Miller K, et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol 2005;23(Suppl.):196S.
  19. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002;29(Suppl. 11):29-37.
  20. Pegram M, Chan D, Dichmann RA, et al. Phase II combined biological therapy targeting HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and beva-cizumab (B) as first line treatment of HER2-am-plified breast cancer. Breast Cancer Res Treat 2006;100(Suppl. 1):S28.
  21. Sledge G, Miller K, Moisa CG, et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer (XCALIBr Trial). J Clin Oncol 2007;25(Suppl.):18S.
  22. Miller KD, Sweeney CJ, Sledge GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-206.
  23. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2 methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-72.
  24. Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to antiangiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20:79-86.
  25. Miller KD, Sweeney CJ, Sledge GW. The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol 2003;14:20-28.
  26. Brouty-Boyn D, Kolonias D, Wu CJ, et al. Relationship of multidrug resistance to rhodami-ne-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux. Cancer Res 1995;55:1633-38.
  27. Hari M, Loganzo F, Annable T, et al. Paclitaxel-resistant cells have a mutation in the paclitaxelbinding region of betatubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 2006;5:270-78.
  28. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005;438:820-27.
  29. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12: 895904.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2008

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies